Results 21 to 30 of about 35,836 (258)

Dual FGFR-targeting and pH-activable Smart Ruthenium-Peptide Conjugates for targeted therapy of Breast Cancer [PDF]

, 2023
Dysregulation of Fibroblast Growth Factor Receptors (FGFRs) signaling has been associated with breast cancer, yet employing FGFR-targeted delivery systems to improve cytotoxic agents is still sparsely exploited.
Marco, Sá, Inês, Pires, Jaime, A. S. Coelho, Miguel , Machuqueiro, João D. G. , Correia, Tânia , Morais, Filipa , Mendes, João , Franco Machado, Maria Helena, Garcia, M. Fátima , M. Piedade, María , Angeles Jiménez, Miguel , Silva, Fernanda , Marques   +12 more
core   +1 more source

FGFR/RACK1 interacts with MDM2, promotes P53 degradation, and inhibits cell senescence in lung squamous cell carcinoma

Cancer Biology & Medicine, 2021
Objective: FGFR is considered an important driver gene of lung squamous cell carcinoma (LSCC). Thus, identification of the biological events downstream of FGFR is important for the treatment of this malignancy.
Tao Chen, Fei Wang, Shupei Wei, Yingjie Nie, Xiaotao Zheng, Yu Deng, Xubin Zhu, Yuezhen Deng, Nanshan Zhong, Chengzhi Zhou   +9 more
doaj   +1 more source

Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases

Cancer Biology & Medicine, 2021
Objective: Dysfunction in fibroblast growth factor receptor (FGFR) signaling has been reported in diverse cancer types, including non-small cell lung cancer (NSCLC).
Zhen Zhou, Zichuan Liu, Qiuxiang Ou, Xue Wu, Xiaonan Wang, Yang Shao, Hongyan Liu, Yu Yang   +7 more
doaj   +1 more source

Resistance to Selective FGFR Inhibitors in FGFR- Driven Urothelial Cancer

Cancer Discovery, 2023
Abstract Several fibroblast growth factor receptor (FGFR) inhibitors are approved or in clinical development for the treatment of FGFR-driven urothelial cancer, and molecular mechanisms of resistance leading to patient relapses have not been fully explored.
Francesco Facchinetti, Antoine Hollebecque, Floriane Braye, Damien Vasseur, Yoann Pradat, Rastislav Bahleda, Cédric Pobel, Ludovic Bigot, Olivier Déas, Juan David Florez Arango, Giorgia Guaitoli, Hayato Mizuta, David Combarel, Lambros Tselikas, Stefan Michiels, Sergey I. Nikolaev, Jean-Yves Scoazec, Santiago Ponce-Aix, Benjamin Besse, Ken A. Olaussen, Yohann Loriot, Luc Friboulet   +21 more
openaire   +3 more sources

Dysregulation of the MACF1-Rab14/KIF16B-FGFR Vesicular Trafficking Axis Skews MSC Lineage Commitment in Glucocorticoid-Induced Osteoporosis. [PDF]

Adv Sci (Weinh)
Under normal conditions, MACF1 interacts with Rab14 and facilitates KIF16B‐mediated FGFR vesicle trafficking along microtubules to the plasma membrane, thereby supporting BMSC differentiation. In contrast, chronic GC exposure suppresses MACF1 expression, disrupting this transport and causing intracellular FGFR retention, which blunts osteogenic ...
Su P, Tian Y, Zhao F, Li J, Patil S, Zhu C, Tian Y, Wang J, Liu J, Xiang A, Guan H, Zhang L, Chen X, Qian A, Yu Q.   +14 more
europepmc   +2 more sources

Targeting FGFR inhibition in cholangiocarcinoma [PDF]

Cancer Treatment Reviews, 2021
Los colangiocarcinomas (CCA) son tumores raros pero agresivos de los conductos biliares, que a menudo se diagnostican en una etapa avanzada y tienen malos resultados en la terapia sistémica. Se han identificado alteraciones somáticas con implicaciones terapéuticas en casi la mitad de las CCA, en particular en la CCA intrahepática (iCCA), el subtipo que
Lipika Goyal, Sarinya Kongpetch, Valerie Crolley, John Bridgewater   +3 more
openaire   +3 more sources

Favorable Outcomes in FGFR Fusion-Positive Cholangiocarcinomas and Evolution on Treatment Noted on Circulating Tumor DNA Liquid Biopsies

Case Reports in Oncology, 2020
Cholangiocarcinoma is a very heterogenous cancer and “target-rich” disease. While the current classifications are based on the anatomic location of these tumors (intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer ...
Pashtoon Murtaza Kasi
doaj   +1 more source

Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment

Molecular Cancer, 2023
Background Fibroblast growth factors (FGFs) and their receptors (FGFRs) play a crucial role in cell fate and angiogenesis, with dysregulation of the signaling axis driving tumorigenesis. Therefore, many studies have targeted FGF/FGFR signaling for cancer
Ruiwen Ruan, Li Li, Xuan Li, Chunye Huang, Zhanmin Zhang, Hongguang Zhong, Shaocheng Zeng, Qianqian Shi, Yang Xia, Qinru Zeng, Qin Wen, Jingyi Chen, Xiaofeng Dai, Jianping Xiong, Xiaojun Xiang, Wan Lei, Jun Deng   +16 more
doaj   +1 more source

Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study. [PDF]

, 2022
BACKGROUND Patients with advanced squamous-cell lung cancer (SQCLC) frequently (46%) exhibit tumor overexpression of fibroblast growth factor receptor (FGFR) messenger ribonucleic acid (mRNA). Rogaratinib is a novel oral pan-FGFR inhibitor with a good
Calgua, Byron, Waibel, Christine, Jermann, Philip M, Haefliger, Simon, Alborelli, Ilaria, Joerger, Markus, Mach, Nicolas, Addeo, Alfredo, Savic-Prince, Spasenija, Holer, Lisa, Fernandez, Eugenio, Rothschild, Sacha I, Mauti, Laetitia, Früh, Martin, Mark, Michael, Schneider, Martina   +15 more
core   +2 more sources

Fibroblast growth factor receptor fusions in cancer: opportunities and challenges

Journal of Experimental & Clinical Cancer Research, 2021
Fibroblast growth factors (FGFs) and their receptors (FGFRs) play critical roles in many biological processes and developmental functions. Chromosomal translocation of FGFRs result in the formation of chimeric FGFR fusion proteins, which often cause ...
Lingfeng Chen, Yanmei Zhang, Lina Yin, Binhao Cai, Ping Huang, Xiaokun Li, Guang Liang   +6 more
doaj   +1 more source